Teladoc (NYSE:TDOC) has been assigned a $46.00 target price by Wells Fargo in a research report issued to clients and investors on Friday. The firm presently has a “buy” rating on the health services provider’s stock. Wells Fargo’s price objective points to a potential upside of 17.50% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the stock. KeyCorp reaffirmed an “overweight” rating and set a $50.00 price target (up previously from $41.00) on shares of Teladoc in a research report on Thursday, March 15th. Deutsche Bank cut shares of Teladoc from a “buy” rating to a “hold” rating and set a $45.00 price target on the stock. in a research report on Thursday, March 15th. Canaccord Genuity increased their price target on shares of Teladoc from $43.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Chardan Capital reaffirmed a “buy” rating and set a $47.00 price target (down previously from $48.00) on shares of Teladoc in a research report on Wednesday, February 28th. Finally, ValuEngine raised shares of Teladoc from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $41.67.
NYSE:TDOC opened at $39.15 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.87 and a quick ratio of 3.87. The stock has a market capitalization of $2,555.48, a price-to-earnings ratio of -23.73 and a beta of 0.36. Teladoc has a 1-year low of $22.73 and a 1-year high of $44.65.
In related news, CFO Mark Hirschhorn sold 100,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $39.60, for a total transaction of $3,960,000.00. Following the sale, the chief financial officer now owns 98,960 shares in the company, valued at $3,918,816. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jason N. Gorevic sold 40,000 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $43.27, for a total transaction of $1,730,800.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 364,494 shares of company stock worth $14,665,947. 4.47% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its stake in Teladoc by 2.3% during the third quarter. Bank of New York Mellon Corp now owns 285,788 shares of the health services provider’s stock worth $9,474,000 after acquiring an additional 6,396 shares during the period. Strs Ohio raised its stake in Teladoc by 33.3% during the fourth quarter. Strs Ohio now owns 304,226 shares of the health services provider’s stock worth $10,602,000 after acquiring an additional 76,057 shares during the period. New York State Common Retirement Fund raised its stake in Teladoc by 33.2% during the third quarter. New York State Common Retirement Fund now owns 90,513 shares of the health services provider’s stock worth $3,001,000 after acquiring an additional 22,554 shares during the period. ARK Investment Management LLC raised its stake in Teladoc by 211.7% during the fourth quarter. ARK Investment Management LLC now owns 31,321 shares of the health services provider’s stock worth $1,092,000 after acquiring an additional 21,274 shares during the period. Finally, Gamco Investors INC. ET AL acquired a new stake in Teladoc during the fourth quarter worth about $941,000.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3339928/teladoc-tdoc-given-a-46-00-price-target-at-wells-fargo.html.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.